A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic

Sanofi

Status: Completed

Conditions: Atopic Dermatitis

Study type: Observational

Funder types: Industry

Identifiers

NCT05527964

U1111-1279-3216 (Registry Identifier)

OBS17350

Details and patient eligibility

About

Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24.

Description of the:

• Change in disease activity after 16 and 24 weeks
• Change in subject and family quality of life after 16 and 24 weeks
• Change in sleep quality after 16 and 24 weeks
• Change in anxiety after 16 and 24 weeks
• Change in depression after 16 and 24 weeks
• Safety and tolerability

Full description

28 weeks

Enrollment: 146 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL
• Signed informed consent
• 18 years and older (study questionnaires are validated for this age group). Patient is able to follow the prescribed regimen, routine follow-up visits and to fill the questionnaires

Exclusion criteria

• Patient not eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Trial design

146 participants in 1 patient group

Patients with severe refractory atopic dermatitis

Description:

Patients eligible for Dupixent therapy of AD